Simon Ward

Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom.

Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom.

Incanthera Plc operates as a holding company, which focuses on drug discovery and development of targeted medicines for the treatment of cancer. The firm products include Sol, EP0015, Equin & Duo-C. The company was founded on March 2, 2010 and is headquartered in Manchester, the United Kingdom.

Incanthera Oncology Ltd. engages in the provision of drug development services. The company was founded on April 7, 2011 and is headquartered in Manchester, the United kingdom.

York Pharma (R&D) Ltd. manufactures pharmaceutical products. It is primarily concerned with developing solutions for skin diseases including psoriasis, eczema, cancer, and photo ageing. The company provides therapeutic strategies from new drug discovery to improved methods of diagnosis and novel delivery mechanisms. The company was founded in 2003 and is headquartered in Milton Keynes, GB.

Medipex Ltd. provides technology and knowledge transfer services to the National Health Service. It provides a range of services to NHS organizations to help them identify, protect and commercialize Intellectual Property owned by them through the work of their employees. The company was founded in 2002 and is headquartered in Leeds, the United Kingdom.

York Pharma Plc activity is acquiring, developing and commercialising prescription dermatological products. It focuses on a dermatological product called abafungin, a topical therapy intended for the treatment of fungal infections and some mixed microbial infections. The Group's product will be marketed under the trade mark Abasol. The Group's other product brands are Sabarep and Vampex. The Group operates in the United Kingdom, Japan and Germany.